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What is the key question? 
What is the current prevalence of Hereditary Haemorrhagic Telangiectasia (HHT) in the UK 
and how does it vary with respect to age, sex, socioeconomic status and geographical 
location?  
What is the bottom line?  
Using a representative UK general practice database we estimate the prevalence of HHT to 
be at least 1 per 9,500 which is more common than previously documented in the UK, 
though still likely to represent an underestimate of the true prevalence. 
Why read on? 
We identify particular under-recognition in the diagnosis of HHT in males and those from 
less affluent socioeconomic groups with a significant variation in diagnostic rates between 
different geographical regions of the UK.   
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ABSTRACT  
Background 
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder of 
aberrant blood vessel development characterised by arteriovenous malformations. HHT is 
associated with significant morbidity due to complications including epistaxis, 
gastrointestinal bleeding and stroke and may be associated with reduced life expectancy. 
We explored the hypothesis that a diagnosis of HHT is associated with sex, socioeconomic 
status and geographical location. 
 
Methods 
We used The Health Improvement Network, a longitudinal, computerised general practice 
database covering 5% of the UK population to calculate prevalence estimates for HHT 
stratified by age, sex, socioeconomic status and geographical location. 
 
Results 
The 2010 UK point prevalence for HHT was 1.06 per 10,000 person years [95% confidence 
interval (CI): 0.95-1.17] or 1 in 9400 individuals. The diagnosed prevalence of HHT was 
significantly higher in females compared to males [adjusted prevalence rate ratio (PRR) 1.53, 
95% CI: 1.24-1.88] and in those from the most affluent socioeconomic group compared to 
the least [adjusted PRR 1.74, 95% CI: 1.14-2.64]. The PRR varied between different regions 
of the UK being highest in the South West and lowest in the West Midlands [adjusted PRR 
for former compared to latter 1.86, 95% CI: 1.61-2.15]. 
Conclusions 
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HHT is much more common in the UK population than previously demonstrated, though this 
updated figure is still likely to be an underestimate of the true prevalence. HHT appears to 
be significantly under-diagnosed in men which is likely to reflect their lower rates of 
consultation with primary care services, though it is possible that there may be a gender 
differential in disease severity and hence presentation. There is significant under-diagnosis 
in patients from lower socioeconomic groups and a marked variation in the prevalence of 
diagnosis between different geographical regions across the UK that requires further 
investigation.  
 
 
INTRODUCTION 
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder of 
blood vessel development characterised by mucocutaneous telangiectases and by 
arteriovenous malformations (AVMs) in solid organs[1, 2]. HHT is associated with significant 
morbidity due to bleeding complications such as epistaxis and gastrointestinal haemorrhage 
and from embolic complications including cerebral abscess and stroke[3], which are often 
associated with pulmonary arteriovenous malformations (PAVMS)[4]. HHT may also be 
associated with reduced life expectancy[5, 6].  
HHT can be identified by clinical or genetic screening of family members of affected 
individuals but is too often diagnosed as a result of advanced complications of the disease. A 
recent expert panel has recommended screening all possible or confirmed HHT cases for 
PAVMs[7]. Population-based epidemiological studies in HHT are the essential first step in 
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understanding and quantifying the burden of disease and informing healthcare planning for 
this under-recognised condition. There are few data regarding differences in geographical 
prevalence of HHT in the UK or associations with sex, age and socioeconomic status, and 
this is important as understanding these relations may increase knowledge of factors that 
modify both development and diagnosis of the disease. 
Hence, the aim of this study was to determine, using a representative sample of the UK 
population obtained via an electronic general practice database, a contemporary prevalence 
of diagnosed HHT and its association with age, sex, geographical location and deprivation 
status.  
 
 
METHODS 
Study population 
This study utilised an anonymised, computerised, longitudinal general practice database 
known as The Heath Improvement Network (THIN) which has been validated for 
epidemiological research[8, 9]. The THIN database records a variety of patient clinical and 
lifestyle data from consultations both in primary and secondary care including medical 
conditions, symptoms, medications and sociodemographic details. At the time of data 
extraction (September 2011), THIN covered 5% of the UK population with 3.46 million 
patients actively followed prospectively from 440 general practices[10].   
Definition of disease 
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We initially identified all recorded diagnoses (by medical Read codes) between the years 
2000 and 2010 of Hereditary Haemorrhagic Telangiectasia (G770.00) and Rendu-Osler-
Weber Disease (G770.11). Given the high prevalence of HHT in individuals with pulmonary 
AVMs[11] we also searched for Read codes pertinent to pulmonary AVMs (we excluded any 
individuals previously identified as having Read codes for HHT or Rendu-Osler-Weber 
disease to prevent double-counting). Population denominator values were derived from the 
annual mid-year populations contributing to THIN. The results presented in this paper are 
for patients coded as Hereditary Haemorrhagic Telangiectasia (G770.00) or Rendu- Osler-
Weber Disease (G770.11) only. A repeat analysis of a wider population was conducted 
which included all the Read codes listed in Table 1. 
Statistical methods 
Data for 2010 (the most recent complete data year) were used to calculate a point 
prevalence for HHT.  We stratified our results by sex, age group (<15 years, 15-49 years and 
50+ years), geographical location and socioeconomic status. Geographical location was 
defined by UK Health Authority areas and socioeconomic status was based on the Townsend 
index score in quintiles[12]. Given the relatively small numbers available for analysis by 
health authority in 2010, we used combined data from 2000-2010 to calculate prevalence 
estimates for HHT between different health authorities in the UK adjusting for the use of 
repeated measures (see below). We were able to look for any significant changes in the 
prevalence of HHT over the 10 year period between 2000 and 2010. Prevalence estimates 
taken over multiple years were adjusted by direct standardisation to the 2010 THIN 
population. Random effects modelling (Huber’s Method) allowed for the non-independent 
nature of the cases contributing each year to the overall disease prevalence estimate, 
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adjusting the standard errors of the final model. We used Poisson regression to compare 
prevalence rate ratios, controlling for year, age, sex, Townsend score and health authority. 
Statistical tests of significance were performed using the likelihood ratio method unless 
otherwise stated.  All analyses were carried out in Stata SE12 (Stata Statistical Software: 
Stata/SE12.0 for Windows; Stata Corporation, College Station, Texas, USA). The research 
protocol for this study was approved by the THIN Scientific Review Committee. 
 
RESULTS 
We identified a total of 563 individuals diagnosed with HHT/Rendu-Osler-Weber Disease in 
the THIN database from the years 2000–2010 with 365 cases contributing to the calculated 
point prevalence in 2010. Table 1 presents the total number of diagnosed cases identified in 
2010 stratified by Read code.   
 
Disease Read Code N 
   
Hereditary Haemorrhagic Telangiectasia G770.00 342 
Osler Weber 
Rendu                                                                  
G770.11 23 
Sub total  365 
Pulmonary arterio-venous malformation  P736.12 5 
Pulmonary arterio-venous 
fistula                                             
P736.11 6 
Pulmonary arterio-venous 
aneurysm                                     
P736.00 3 
Arteriovenous fistula of pulmonary 
vessels                         
G420.00 17 
 
Total 
  
396 
Table 1. Prevalent cases identified in 2010 from The Health Improvement Network 
database summarised by Read code 
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Overall Prevalence 
The point prevalence of HHT in 2010 was 1.06 per 10,000 (95% CI: 0.95-1.17) or 1 per 9,400.  
In the sensitivity analysis using broader diagnostic criteria (combining all Read codes from 
Table 1) the point prevalence in 2010 increased to 1.15 per 10,000 (95% CI: 1.04-1.26) or 1 
per 8,700.  
Prevalence by Sex and Year 
The prevalence of a diagnosis of HHT was strongly related to sex, with a higher prevalence 
rate in females compared to males for all years between 2000 and 2010 (Fig 1). In 2010 the 
point prevalence in women was 1.29 per 10,000 person years (95% CI: 1.12-1.46) and for 
men was 0.82 per 10,000 person years (95% CI: 0.69-96). After adjusting for age, deprivation 
status and geographical location, the prevalence rate ratio (PRR) in 2010 for HHT was higher 
in women compared with men (PRR 1.59, 95% CI: 1.30-1.94, p<0.0001). The prevalence rate 
for both men and women has remained relatively constant over the last 10 years.  
Prevalence by Sex and Age group 
Prevalent cases from 2010 were grouped into 3 different age categories (<15 years, 15-49 
years and 50 years and over) and stratified by sex (Fig 2). The unadjusted prevalence rate in 
both sexes was lowest in those aged <15 years and highest in the 50+ age group though the 
adjusted prevalence rate ratios across the age groups did not differ significantly (p test for 
trend =0.29) (Table 2). 
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 Crude Prevalence 
rates (95% CI) per 
10,000 person-years 
Crude prevalence 
rate ratios (95% CI) 
Mutually adjusted 
prevalence rate 
ratios 
(95% CI)* 
Sex    
Male 0.84 (0.70-0.98) 1.00 1.00 
Female 1.28 (1.11-1.44) 1.56 (1.25-1.95) 1.53 (1.24-1.88) 
   P=0.0001 
Age group (years)    
<15 years 0.61 (1.15-1.77) 1.00 1.00 
15-50 years 0.84 (0.71-0.98) 1.39 (0.88-2.19) 1.39 (0.96-2.02) 
>50 years 1.58 (1.35-1.81) 2.62 (1.69-4.07) 2.53 (1.76-3.63) 
   p<0.0001  
p=0.29ᵒ 
Townsend Score    
1 (Least deprived) 1.31 (1.07-1.55) 1.93 (1.29-2.89) 1.74 (1.14-2.64) 
2 1.05 (0.81-1.29) 1.55 (1.701-2.38) 1.36 (0.88-2.11) 
3 1.10 (0.85-1.35) 1.62 (1.03-2.55) 1.50 (0.97-2.31) 
4 0.87 (0.63-1.10) 1.28 (0.79-2.08)  1.23 (0.78-1.94) 
5 (Most deprived) 0.68 (0.43-0.93) 1.00 1.00 
9 (Missing values) 1.34 (0.77-1.91) 1.98 (1.12-3.52) 2.20 (1.25-3.88) 
   P=0.026 
Table 2. Crude prevalence rates and prevalence rate ratios of HHT derived from Poisson 
regression modelling using The Health Improvement Network dataset in 2010. 
*Adjusted for sex, age group, Townsend score and health authority 
ᵒp-trend across age categories  
 
 
Prevalence by Deprivation status 
The prevalence of HHT was inversely associated with socioeconomic deprivation (Table 2). 
The crude prevalence rate in the most deprived group (Townsend score: quintile 5) was 0.68 
per 10,000 (95% CI: 0.43-0.93) compared to 1.31 per 10,000 in the least deprived quintile 
(95% CI: 1.07-1.55).  After adjusting for the effects of age, gender and geographical location, 
the prevalence rate ratio was higher in those in the least deprived socioeconomic group 
when compared to those in the most deprived group (PRR 1.74, 95% CI: 1.14-2.64, 
p<0.0001).  
Prevalence by Health Authority 
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There was substantial variation in estimates of the crude prevalence of HHT across the UK 
when stratified by health authority over the 10 year period 2000-2010 (Fig 3). The adjusted 
prevalence rate ratio varied almost twofold across the different UK health authority 
boundaries (PRR 1.86, 95% CI: 1.61-2.15, p<0.0001) with the lowest adjusted prevalence in 
the West Midlands and the highest prevalence in the South West (Table 3). 
 
 
 
Crude prevalence 
rates (95% CI) per 
10,000 person-years 
Crude prevalence 
rate ratios (95% CI) 
Mutually adjusted 
prevalence rate 
ratios 
(95% CI)* 
Health Authority    
West Midlands 0.78 (0.69-0.88) 1.01 (0.85-1.19) 1.00 
East Midlands 0.85 (0.71-1.00) 1.09 (0.89-1.34) 1.08 (0.88-1.33) 
London 0.78 (0.69-0.87) 1.00 1.13 (0.96-1.34) 
South East Coast 1.02 (0.92-1.13) 1.32 (1.13-1.54) 1.30 (1.11-1.52) 
Northern Ireland 0.93 (0.77-1.09) 1.20 (0.97-1.48) 1.30 (1.05-1.61) 
East of England 1.07 (0.95-1.18) 1.37 (1.16-1.61) 1.35 (1.15-1.59) 
Scotland 1.07 (0.97-1.17) 1.37 (1.18-1.59) 1.45 (1.25-1.69) 
North West 1.14 (1.03-1.25) 1.46 (1.26-1.70) 1.48 (1.27-1.72) 
South Central 1.23 (1.13-1.33) 1.58 (1.37-1.82) 1.54 (1.33-1.77) 
Yorkshire & Humber 1.37 (1.18-1.55) 1.75 (1.46-2.10) 1.76 (1.46-2.11) 
Wales 1.35 (1.20-1.51) 1.73 (1.47-2.04) 1.77 (1.50-2.09) 
North East 1.35 (1.14-1.55) 1.73 (1.42-2.10) 1.80 (1.48-2.19) 
South West 1.51 (1.39-1.63) 1.94 (1.68-2.23) 1.86 (1.61-2.15) 
   p<0.0001 
Table 3. Crude prevalence rates and prevalence rate ratios derived from Poisson 
regression modelling of HHT prevalence using The Health Improvement Network 
dataset between 2000 and 2010 
*Adjusted for age, sex and Townsend score 
 
Sensitivity Analysis 
The above analyses were repeated to include all Read codes listed in Table 1, rather than 
those for HHT and Rendu-Osler-Weber Disease alone and revealed no significant differences 
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in qualitative trends of our results nor significance values for these trends. There was a 
slight change in the prevalence rate ratios calculated for the different health authority areas 
in the sensitivity analysis, with HHT or PAVMs diagnosed most commonly in Yorkshire rather 
than the South West (data not shown). 
 
 
DISCUSSION 
Summary of results 
This is the first study to use a national primary care population-based database to explore 
sex, socioeconomic and regional differences in the prevalence of hereditary haemorrhagic 
telangiectasia, as well as providing national prevalence figures for the United Kingdom. The 
2010 point prevalence for HHT in the UK is 1.06 per 10,000 (or 1 per 9,400) which has 
remained relatively stable between 2000 and 2010. The prevalence estimate is higher when 
Read codes likely to be associated with HHT are included (1 per 8,700) and is higher still if 
the prevalence in females is considered to be more representative of the population as a 
whole (1 per 7,800). The prevalence increases with age. The diagnosed prevalence ratio of 
HHT was 59% higher in women than in men and 74% higher in those from the least deprived 
socioeconomic group when compared to those in the most deprived group. In addition, we 
have demonstrated a substantial geographical variation in the diagnosed prevalence of HHT 
across the UK.  
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Strengths and Weaknesses 
This is the first population-based study of HHT using a primary care database in the UK 
general population. With a total of 365 HHT prevalent cases identified in 2010 our study 
sample size is almost four times larger than the last UK estimate undertaken in 1992[13], is 
nationally representative and comparable in size with epidemiological studies conducted in 
other countries[6, 14, 15]. We have been able to stratify our prevalence estimates by sex, 
age group, deprivation status and geographical location without the risk of bias that may 
occur either from low response rates (as have been observed in previous surveys of HHT 
prevalence in the UK[13]) or from case-series in specialist centres which may lack a 
denominator population or represent cases referred for specialist care with potentially 
more severe disease. 
There are potential limitations to the study which should be addressed. The first is that of 
the validity of the HHT diagnoses, which are recorded by general practitioners in the THIN 
database whilst the clinical diagnosis is generally made in secondary care. In practice, we are 
reasonably confident that the vast majority of these diagnoses will be correct with the 
increasing involvement of clinical geneticists in the screening and diagnosis of HHT which 
should result in more reliable information being conveyed to the primary care practitioner, 
and hence entered into the database. It seems very unlikely that a primary care practitioner 
would enter a diagnosis of HHT into the database unless it was supported by 
correspondence from secondary care. The consistency of our calculated prevalence of HHT 
with other comparable estimates from previous studies also supports the reliability of our 
findings. One further limitation that complicates all studies of HHT prevalence at present is 
the likelihood of undiagnosed individuals with HHT at large in the community. This may 
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explain the higher prevalence of PAVMs as defined by radiological criteria (and by inference, 
HHT) in patients who were participating in a recent Japanese CT screening program for lung 
cancer[16] than we observed in our dataset which did not use this radiological definition of 
the disease. Diagnosis is often confounded by the heterogeneous clinical presentation of 
HHT due to its variable genetic penetrance and expressivity[17]. An average time lag of 25 
years separates disease onset and first definite diagnosis[18]. Hence, our prevalence 
estimates represent those with diagnosed HHT, and are likely to be lower than the true 
prevalence defined as all individuals with a mutation compatible with the disease. The fact 
that our data show the prevalence of the disease has been stable in both sexes over the last 
decade would suggest that the consistency in coding practice over this period has been 
maintained.   
We used the Townsend score which is a deprivation index based on area as it was not 
possible to access individual-level deprivation data. This score presumes that individuals 
living within a geographical area have a similar deprivation status which may not be the 
case. However, there is evidence to suggest that the Townsend scores calculated at a district 
level are good proxy measures for individual levels of deprivation[19].  
Interpretation of results 
Reasons for the marked sex difference between the diagnosed prevalence of HHT require 
careful consideration. One study from the Dutch Antilles showed a 33% increased 
prevalence ratio of a ‘definite’ diagnosis of HHT in females compared with males (using the 
Curacao criteria)[15], and a recent US paper found a female:male ratio of 1.54, with HHT 
being diagnosed more commonly in females[20]. Other studies have reported a more 
balanced distribution between sexes[14, 17]. Given HHT is an autosomal dominant disorder, 
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the offspring of affected individuals will have a 50% chance of inheriting a mutation and this 
should not per se be associated with a sex bias. Our data show a significant difference in 
diagnosis of HHT in women compared with men which appears to be greatest between the 
ages of 15 and 49. One possible explanation for this observation is that the higher diagnosed 
prevalence of HHT in females we observed is due to a difference in access to healthcare 
resources. Women have significantly higher rates of consultation with primary care 
providers during the ages of 15 to 70 years with many consultations due to issues 
surrounding contraception, pregnancy and childcare, and this may explain an increased 
ascertainment of symptomatic females with HHT[21, 22].  A possible alternative explanation 
for the disparity between sexes may be that the expression of the HHT phenotype is more 
common in females with the gene mutation. Little is known about the role of other genetic 
factors (such as moderator genes) or environmental factors that may modify the HHT 
phenotype but there is limited evidence that symptoms such as epistaxis may be amenable 
to treatment via manipulation of oestrogen and progesterone levels[23]. During pregnancy 
there is an increased risk of developing complications of HHT[24, 25] and it has been 
suggested that this may represent a modification of the HHT vasculature by female 
hormones or be secondary to the haemodynamic changes of pregnancy. Clarifying whether 
the sex differential in diagnosis of HHT is due solely to behavioural factors or may be partly 
due to biological reasons is an important area for further research.  
The reduced prevalence of diagnosed HHT in those from lower socioeconomic groups has 
multiple potential explanations which encompass controversial issues such as the proximity 
and quality of healthcare services provided in more deprived areas, as well as differentials in 
individuals’ thresholds for accessing these services across different socioeconomic groups. It 
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is internationally recognised that health and healthcare access inequities vary along social 
gradients[26] and one study looking at health seeking behaviour in those from more 
deprived areas with asthma found that these populations reported a higher prevalence of 
respiratory symptoms but had lower consultation rates for those symptoms[27]. 
Explanations such as varying access to health care, differing perceptions of symptom 
severity or less positive views of health care services were postulated to explain this 
disparity[27, 28].   
Finally, we have observed an almost two-fold difference in diagnosed prevalence 
throughout the UK; least common in the West Midlands and most common in the South 
West.  A pattern of geographical variability has been seen in in other studies, most notably 
in the landmark French paper which first identified a particularly high concentration of 
affected individuals in the Ain, Jura and Deux-Sevres regions of the country[29].  They 
attributed their findings to a local founder effect where an initial new mutation had given 
rise to a cluster of affected individuals that then gradually moved by diffusion to involve 
other nearby regions[30]. It is not possible to say whether our findings could represent 
genetic clusters of the disease in the UK or if they are the result of variations in local primary 
or secondary care recording practice or access to healthcare resources.  Further work should 
try to address this as there may be regions of the UK with a disproportionate under-
diagnosis of HHT, thus exposing individuals to the avoidable risk of the complications of this 
disease. 
Comparison with existing literature 
Table 4 provides a summary of the HHT prevalence estimates of different studies conducted 
worldwide over the last 25 years. Each study has investigated different populations using 
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different methodologies which, in part, explains the differing results. Certain areas such as 
the Dutch Antilles and the Ain department of France have shown particularly high 
prevalence of the disease.  Elsewhere, most studies indicate a prevalence between 1 and 1.6 
per 10,000 (or between 1 per 6,000 and 1 per 10,000) and our study estimate falls within 
this range, although data from individuals with health insurance in the USA provide 
estimates as low as 1 per 33,000[20]. Our findings with respect to age are consistent with 
previous work with the prevalence of HHT being higher in older age groups, suggesting  that 
the disease has an age-related penetrance[17] or alternatively that the likelihood of 
diagnosis is related to longevity. No other studies have looked at the prevalence of diagnosis 
by deprivation status and most studies have been restricted to a small geographical area 
excepting the epidemiological data from France which also shows a wide variation in 
prevalence depending on geographical location[29, 31, 32]. Further research should 
consider the influence of disease severity on the diagnosed prevalence rate and its 
potentially confounding effect on our observations with respect to sex, socioeconomic 
status and geographical location.  
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Year of 
study 
Year of 
estimate 
Authors Study setting and methodology Study size Prevalence 
rate 
(per 10,000) 
Prevalence 
rate 
2013 2010 Donaldson et al UK primary care database 365 1.06 1 per 9,400 
2013 2005-
2010 
Grosse et al[20] US health insurance database 1203 0.3 1 per 33,000 
 2003 1998 Westermann  et 
al [15] 
Screening extended pedigree of 
previously identified cases in 
Antilles, Netherlands 
112 7.51 1 per 1,300 
2002 2002 Dakeishi et 
al[14] 
Screening extended pedigree of 
cases referred to tertiary centre 
in Akita prefecture, Northern 
Japan 
23 1.25 
 
1 per 8,000 
1999 1995 Kjeldsen et al[6] Regional patient database, Fyne 
county, Denmark 
73 1.56 
 
1 per 6,400 
1995 1994 Guttmacher et 
al[33] 
Postal questionnaire of 
identified cases in Vermont, USA 
34 0.61 1 per 16,400 
1992 1991 
 
Jessurun et 
al[34] 
Study of cases hospitalised to 
one centre in Leeward Islands, 
Antilles, Netherlands 
32 1.94 
 
1 per 5,200 
1992 1990 Porteous et 
al[13] 
Postal questionnaire study of 
cases in Newcastle, “Northern 
Region”, UK 
79 0.25 
 
1 per 40,000 
1989 1989 Bideau et al[29] Postal questionnaire study of 
cases identified by physicians in 
France (52 departments) 
406 
 
1.20 
 
1 per 8,300 
1984 1983 Plauchu et al[31] Postal questionnaire study of 
cases identified by physicians in 
Ain department, France 
150 
 
4.25 1 per 2,400 
Table 4. Summary of previous prevalence studies of HHT 
 
Implications  
This is the first contemporary study in a representative UK population to estimate the 
prevalence of HHT and suggests that it is much more common than the previously thought, 
and similar to the prevalence seen in other countries. Assuming that the prevalence of HHT 
in males is the same as for females, the “true” estimate of total prevalence would be closer 
to 1.28 per 10,000 or 1 per 7800 (the figure calculated for females alone). A similar 
approach extrapolating the “true” prevalence from females living in the South West of the 
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UK (the health authority with the highest crude prevalence of HHT) estimates a prevalence 
of 1.9 per 10,000 and would equate to at least 11,800 cases of HHT in a population of 62.3 
million in 2010[35]. The lower diagnostic rate of HHT in males and those from less affluent 
social backgrounds suggests a sociological (or alternatively a biological role) in the 
presentation of HHT, while the previously unreported regional differences is an observation 
that requires validation in other datasets. Future research would ideally draw on a national 
rare disease database with integrated clinical information and genetic samples allowing 
greater understanding of the presentation of the disease, the genotype-phenotype 
relationship in HHT and the influences upon it of moderator genes and external 
environmental factors.  
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Fig 1. The UK prevalence of hereditary haemorrhagic telangiectasia by sex and year (2000-
2010) with total prevalent cases tabulated 
 
Fig 2. The prevalence of hereditary haemorrhagic telangiectasia by sex and age group in 
2010 
 
Fig 3. The crude prevalence of hereditary haemorrhagic telangiectasia (per 10,000) by UK 
health authority area (2000-2010) 
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